Reolysin well-tolerated in phase I patients, Oncolytics says

By E. Janene Geiss

Philadelphia, Oct. 19 - Oncolytics Biotech Inc. announced Wednesday that patients in its Canadian phase I clinical trial of Reolysin for recurrent malignant glioma appeared to tolerate the treatment well.

According to a company news release, the primary purpose of the Canadian study, which is now complete, was to determine the safety of Reolysin, an intratumoral injection, in 12 patients with malignant gliomas that had recurred despite other treatments including surgery and radiation.

After treatment with Reolysin, phase I patients were monitored and evaluated for six months, officials said.

The company previously reported that Reolysin appeared to be well-tolerated when surgically delivered into the brain during the treatment of the first six patients enrolled in the study.

Clinical investigators will present more information when the results are available.

A similar U.S. study will use an alternative method of delivery using product made with the company's current manufacturing process, Brad Thompson, president and chief executive officer of Oncolytics, said in the release.

The company plans to investigate the use of Reolysin in phase II studies for malignant glioma in combination with both chemotherapeutics and radiation therapy, Thompson said.

Oncolytics is a Calgary, Alta.-based biotechnology company focused on the development of Reolysin to treat cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.